PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Bronchiectasis

Drugs in development · updated 30 October 2026

Bronchiectasis: drugs in development

As of 30 October 2026 there are 9 active clinical trials (recruiting or ongoing, phases I–III) on 8 drugs for bronchiectasis. 5 are experimental, that is not yet approved in the United States.

9Active trials
5Experimental drugs
2Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
BI 1291583III2NCT06872892
CHF10196III1NCT07577804
GSK3862995BII1NCT07201051
HSK31858II1NCT06820749
CTX-187I1NCT07708116

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
AzithromycinAzasite®, Zithromax®III1NCT06409299
ItraconazoleTolsura®, Onmel®III1NCT06160713
MoxifloxacinIZILOX, Moxeza®III1NCT07274020

Sorted by most advanced phase and number of active trials.

All 8 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D001987 “Bronchiectasis”.

ItalianoFrançaisDeutsch